Evaluating Triple Therapy in COPD Management

This chapter explores the management of chronic obstructive pulmonary disease (COPD), highlighting the role of combining long-acting beta agonists and muscarinic antagonists. It reviews findings from a 2023 Cochrane review regarding the impact of adding inhaled corticosteroids, noting both improved quality of life and increased pneumonia risk associated with triple therapy.